Cyclophosphamid (Cytoxan, Endoxan, Neosar)
Other Medications · Approved since 1959
Description
Cyclophosphamide is an alkylating chemotherapy agent that serves as a lymphodepleting medication in adoptive cell therapy protocols for metastatic colorectal cancer. In CRC treatment, it is primarily used as part of conditioning regimens before tumor-infiltrating lymphocyte (TIL) therapy or engineered T-cell therapies targeting KRAS mutations. The drug creates an immunosuppressive environment that enhances the engraftment and expansion of infused therapeutic immune cells in patients with treatment-refractory metastatic disease.
Mechanism of Action
Cyclophosphamide cross-links DNA strands through its active metabolites, phosphoramide mustard and acrolein, leading to cell death particularly in rapidly dividing cells. In the context of adoptive immunotherapy, it preferentially depletes regulatory T-cells and other immunosuppressive cells, creating space and reducing competition for homeostatic cytokines like IL-7 and IL-15 that support therapeutic T-cell expansion.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Cytoxan, Endoxan, Neosar |
| Category | Other Medications |
 Status | FDA Approved |
| Administration | IV, Oral |
| Year Approved | 1959 |
| Clinical Trials | 40 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.